TDOC Stock Analysis: Teladoc | NYSE
Health Information Services | NYSE, USA | Market Cap: 1.250m USD | 12M Return: 6.1% | US87918A1051 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 22.0M
Qual. Beats: 1
Rev. Trend: -97.8%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Teladoc Health, Inc. (NYSE: TDOC) is a U.S.-based virtual healthcare provider that operates across two main segments: Integrated Care and BetterHelp. The Integrated Care segment delivers general, expert, and specialty medical services, along with chronic condition management and mental health support, while also supplying enterprise telehealth solutions to hospitals and health systems. The BetterHelp segment runs a direct-to-consumer mental health platform offering online counselling and therapy through websites, mobile apps, phone, and text-based interactions with licensed clinicians. The companys products are sold under the Teladoc and BetterHelp brands to employers, health plans, hospitals, insurers, financial services firms, and individual members.
Founded in 2002 and headquartered in New York, the company was originally incorporated as Teladoc, Inc. before adopting its current name in August 2018. It went public on the NYSE in July 2015 and is classified within the Health Care Technology sub-industry, a segment that includes firms delivering digital tools, remote care platforms, and software-enabled services to healthcare providers, payers, and consumers.
- BetterHelp subscriber growth drives consolidated revenue
- Integrated Care segment margins face enterprise contract pressure
- Competition intensifies from Cerebral and Lyra Health
| Net Income: -154.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 1.48 > 1.0 |
| NWC/Revenue: -7.68% < 20% (prev 27.20%; Δ -34.88% < -1%) |
| CFO/TA 0.10 > 3% & CFO 268.4m > Net Income -154.8m |
| Net Debt (215.3m) to EBITDA (236.1m): 0.91 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (181.9m) vs 12m ago 3.53% < -2% |
| Gross Margin: 73.18% > 18% (prev 69.80%; Δ 3.38% > 0.5%) |
| Asset Turnover: 87.31% > 50% (prev 87.83%; Δ -0.52% > 0%) |
| Interest Coverage Ratio: -6.67 > 6 (EBIT TTM -135.8m / Interest Expense TTM 20.4m) |
| A: -0.07 (Total Current Assets 1.23b - Total Current Liabilities 1.42b) / Total Assets 2.78b |
| B: -5.97 (Retained Earnings -16.6b / Total Assets 2.78b) |
| C: -0.05 (EBIT TTM -135.8m / Avg Total Assets 2.83b) |
| D: 0.87 (Book Value of Equity 1.29b / Total Liabilities 1.48b) |
| Altman-Z'' = -19.31 = D |
| DSRI: 1.08 (Receivables 230.9m/219.5m, Revenue 2.47b/2.53b) |
| GMI: 0.95 (GM 69.80% / 73.18%) |
| AQI: 0.90 (AQ_t 0.54 / AQ_t-1 0.60) |
| SGI: 0.98 (Revenue 2.47b / 2.53b) |
| TATA: -0.15 (NI -154.8m - CFO 268.4m) / TA 2.78b) |
| Beneish M = -3.09 (Cap -4..+1) = AA |
As of October 30, 2026, the stock is trading at USD 8.73 with a total of 20,001,653 shares traded. Over the past week, the price has changed by +38.13%, over one month by +51.83%, over three months by -4.90% and over the past year by +6.08%.
Current recommended Stop Loss: 8.30 (which is 4.9% or 1.6 ATR below the current price).
Teladoc has received a consensus analysts rating of 3.48. Therefore, it is recommended to hold TDOC.
- StrongBuy: 5
- Buy: 1
- Hold: 17
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 7.5 | -14.4% |
P/E Forward = 303.0303
P/S = 0.5021
P/B = 0.8945
P/EG = -1.01
Revenue TTM = 2.47b USD
EBIT TTM = -135.8m USD
EBITDA TTM = 236.1m USD
Long Term Debt = 994.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 997.6m USD (from shortTermDebt, last quarter)
Debt = 1.07b USD (from shortLongTermDebtTotal, last quarter) + Leases 39.5m
Net Debt = 215.3m USD (calculated: Debt 1.07b - CCE 849.9m)
Enterprise Value = 1.47b USD (1.25b + Debt 1.07b - CCE 849.9m)
Interest Coverage Ratio = -6.67 (Ebit TTM -135.8m / Interest Expense TTM 20.4m)
EV/FCF = 6.30x (Enterprise Value 1.47b / FCF TTM 232.6m)
FCF Yield = 15.88% (FCF TTM 232.6m / Enterprise Value 1.47b)
FCF Margin = 9.43% (FCF TTM 232.6m / Revenue TTM 2.47b)
Net Margin = -6.27% (Net Income TTM -154.8m / Revenue TTM 2.47b)
Gross Margin = 73.18% ((Revenue TTM 2.47b - Cost of Revenue TTM 662.0m) / Revenue TTM)
Gross Margin QoQ = 68.56% (prev none%)
Tobins Q-Ratio = 0.53 (Enterprise Value 1.47b / Total Assets 2.78b)
Interest Expense / Debt = 1.91% (Interest Expense 20.4m / Debt 1.07b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -107.3m (EBIT -135.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.87 (Total Current Assets 1.23b / Total Current Liabilities 1.42b)
Debt / Equity = 0.82 (Debt 1.07b / totalStockholderEquity, last quarter 1.29b)
Debt / EBITDA = 0.91 (Net Debt 215.3m / EBITDA 236.1m)
Debt / FCF = 0.93 (Net Debt 215.3m / FCF TTM 232.6m)
Total Stockholder Equity = 1.33b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.48% (Net Income -154.8m / Total Assets 2.78b)
RoE = -11.63% (Net Income TTM -154.8m / Total Stockholder Equity 1.33b)
RoCE = -5.84% (EBIT -135.8m / Capital Employed (Equity 1.33b + L.T.Debt 994.9m))
RoIC = -4.80% (negative operating profit) (NOPAT -107.3m / Invested Capital 2.23b)
WACC = 5.94% (E(1.25b)/V(2.32b) * Re(9.72%) + D(1.07b)/V(2.32b) * Rd(1.91%) * (1-Tc(0.21)))
Discount Rate = 9.72% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.63 | Cagr: 2.98%
[DCF] Terminal Value 77.97% ; FCFF base≈219.1m ; Y1≈251.1m ; Y5≈369.6m
[DCF] Fair Price = 29.43 (EV 5.56b - Net Debt 215.3m = Equity 5.35b / Shares 181.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.67 | # QB: 1
Revenue Correlation: -97.82 | Revenue CAGR: -2.03% | SUE: 2.28 | # QB: 1
EPS current Year (2026-12-31): EPS=-0.79 | Chg30d=-0.43% | Revisions=-17% | GrowthEPS=-19.9% | GrowthRev=-4.3%
EPS next Year (2027-12-31): EPS=-0.72 | Chg30d=+7.86% | Revisions=+0% | GrowthEPS=+8.1% | GrowthRev=-0.9%
[Analyst] Revisions Ratio: -12% (up=2, down=3)